Click here to read this item in full if you are a subscriber to this newsletter
Our Shopping Cart is currently not working; please phone us on +44 870 1657210 in working hours (08.30 to 18.00 UK time) to place your order or, at other times, please email email@example.com specifying the Publication, Title and Issue date of the item you require.
Issue: May 2006, page: 10
Implant aids treatment of distressing condition
Following completion of the active clinical part of a Phase III study of an implant for treating central precocious puberty (CPP), or the early onset of puberty, manufacturer, Valera Pharmaceuticals Inc, plans to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) during this second quarter of 2006.